diltiazem

(redirected from Cardizem la)
Also found in: Dictionary, Thesaurus.
Related to Cardizem la: diltiazem hydrochloride, Tiazac

diltiazem

 [dil-ti´ah-zem]
a calcium channel blocking agent that acts as a vasodilator; used as the hydrochloride salt in treatment of angina pectoris, hypertension, and supraventricular tachycardia

diltiazem

/dil·ti·a·zem/ (dil-ti´ah-zem) a calcium channel blocker that acts as a vasodilator; used as the hydrochloride salt in the treatment of angina pectoris, hypertension, and supraventricular tachycardia.

diltiazem

(dĭl-tī′ə-zĕm′)
n.
A calcium channel blocker drug, C22H26N2O4S, that acts as a coronary vasodilator and is used in the form of its hydrochloride to treat angina pectoris and hypertension.

diltiazem

[diltī′əzam]
a calcium channel blocker or calcium antagonist.
indications It is prescribed for the treatment of vasospastic and effort-associated angina, in addition to hypertension.
contraindications Sick sinus syndrome, second- or third-degree atrioventricular block, or hypotension prohibits its use.
adverse effects Among the more serious adverse reactions are edema, arrhythmia, bradycardia, hypotension, syncope, rash, headache, and dizziness.

diltiazem

Cardizem®, Tiazac® Cardiology A CCB used to the control atrial flutter or A Fib, angina, paroxysmal SVT, and HTN, which may prevent ↓ coronary artery diameter after heart transplantation Adverse effects Atrial flutter, tachyarrhythmias, slowing of AV conduction and sinus node automaticity, pruritus, sweating, constipation, N&V Contraindications WPW syndrome, constipation, peripheral edema, left ventricular dysfunction. See Calcium channel blocker.

diltiazem

A calcium channel blocker drug used in the treatment of ANGINA PECTORIS and high blood pressure (HYPERTENSION). Brand names are Adizem SR, Adizem-XL, Angitil SR, Angitil XL, Dilzem SR, Dilzem XL, Slozem, Tildiem, Tildiem LA, Viazem XL, Zemtard and Zildil SR.

diltiazem

calcium channel-blocking agent, used in the treatment of angina and hypertension (in cases that fail to respond to beta-blockers); see antihypertensive agents

diltiazem

a calcium-channel blocking agent used to produce peripheral and coronary vasodilation in the management of heart disease.
References in periodicals archive ?
For the 12-months ending 31 December 2009, Cardizem LA had total US sales of approximately USD94.
We remain pleased with the continued, above market prescription performance of our cholesterol franchise and the significant contributions from our recent corporate development initiatives involving Azmacort, Cardizem LA, the Teveten franchise and the Barr Laboratories co-promotion alliance in women's healthcare.
sales of Cardizem LA, which is now marketed by Kos Pharmaceuticals, Inc.
Q1/05 Total Rx Q1/04 Total Rx Growth Rate Cardizem LA 401,466 323,412 24% Teveten 142,274 116,956 22% Zovirax 367,897 357,531 3% Promoted Products 911,637 797,899 14% Wellbutrin XL 2,881,026 1,793,183 61% Biovail Pharmaceuticals Canada 767,557 746,154 3% Legacy Products 621,228 861,387 (28%) Generics 1,817,742 1,902,357 (4%) Total Prescriptions 6,999,190 6,100,980 15% Source: IMS
Kos will pay approximately $104 million in cash and will pay Biovail to manufacture and supply Cardizem LA and the Cardizem LA/enalapril product when approved and commercialized.
In addition to Kos obtaining rights to three marketed products, Kos obtains the rights to commercialize a single tablet formulation of Cardizem LA and enalapril, which is in development for the treatment of hypertension and for which an NDA is expected to be submitted to the FDA during the first half of 2007.
With respect to approvals, Biovail received FDA approval for Cardizem LA in the treatment of angina and TPD approval for Tiazac XC in the treatment of hypertension in Canada.
Core products - those that Biovail, or a distribution partner, is actively promoting (represented by Cardizem LA, the Teveten line, Zovirax, BPC and Wellbutrin XL) - generated revenues of $132.
For the first nine months of 2004, revenues for Cardizem LA (launched in April 2003) were $43.
millions) Product Updated Previous Cardizem LA 70 - 80 80 - 100 Teveten 20 - 25 30 - 40 Zovirax 75 - 80 90 - 110 Promoted Products 165 - 185 200 - 250 Wellbutrin XL 275 - 300 200 - 250 Biovail Pharma Canada 100 - 110 100 - 120 Legacy 130 - 150 150 - 200 Generics 120 - 135 110 - 130 Total Product Sales 790 - 880 760 - 950 R&D Revenue 10 - 15 10 - 15 Royalty/Co-Promote 20 - 25 20 - 25 Total Revenue Guidance 820 - 920 800 - 940